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Background: The dorsolateral prefrontal cortex (DLPFC) is a common target for repetitive transcranial
magnetic stimulation (rTMS) in major depression, but the conventional “5 cm rule” misses DLPFC in >1/3
cases. Another heuristic, BeamF3, locates the F3 EEG site from scalp measurements. MRI-guided neu-
ronavigation is more onerous, but can target a speciﬁc DLPFC stereotaxic coordinate directly. The
concordance between these two approaches has not previously been assessed.
Objective: To quantify the discrepancy in scalp site between BeamF3 versus MRI-guided neuronavigation
for left DLPFC.
Methods: Using 100 pre-treatment MRIs from subjects undergoing left DLPFC-rTMS, we localized the
scalp site at minimum Euclidean distance from a target MNI coordinate (X  38 Y þ 44 Z þ 26) derived
from our previous work. We performed nasion-inion, tragusetragus, and head-circumference mea-
surements on the same subjects’ MRIs, and applied the BeamF3 heuristic. We then compared the dis-
tance between BeamF3 and MRI-guided scalp sites.
Results: BeamF3-to-MRI-guided discrepancies were <0.65 cm in 50% of subjects, <0.99 cm in 75% of
subjects, and <1.36 cm in 95% of subjects. The angle from midline to the scalp site did not differ
signiﬁcantly using MRI-guided versus BeamF3 methods. However, the length of the radial arc from vertex
to target site was slightly but signiﬁcantly longer (mean 0.35 cm) with MRI-guidance versus BeamF3.
Conclusions: The BeamF3 heuristic may provide a reasonable approximation to MRI-guided neuro-
navigation for locating left DLPFC in a majority of subjects. A minor optimization of the heuristic may
yield additional concordance.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).from the Canadian Institutes
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Repetitive transcranial magnetic stimulation (rTMS) is a non-
invasive brain stimulation technique that uses powerful, focused
magnetic pulses to induce durable changes in the activity of target
brain regions. In addition to its research applications, rTMS is being
studied as a treatment for a wide variety of neurological and psy-
chiatric conditions [1], ranging from Parkinson’s disease [2] andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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traumatic stress disorder [5], and eating disorders [6,7]. However,
its most common application at present is in the treatment of
medication-resistant major depressive episodes, with efﬁcacy now
demonstrated in dozens of randomized sham-controlled trials
[8e11] and reviewed in several large meta-analyses [12,13]. rTMS is
currently approved for this indication in a number of jurisdictions
including the USA, Canada, the European Union, Australia, New
Zealand, and Israel, with hundreds of clinics currently in operation
and treating tens of thousands of patients annually.
As a focal brain stimulation technique, rTMS differs from con-
ventional antidepressant treatments such as medications or psy-
chotherapy, in being rather more anatomically speciﬁc in its
mechanism of action. For this reason, the efﬁcacy of rTMS depends
critically upon both the choice of stimulation target and upon the
accuracy of the methods used to locate this target for stimulation
[14,15]. In the case of major depression, a variety of potentially
useful rTMS targets have been considered [16]. However, with a few
exceptions [17,18], the vast majority of clinical trials and therapeutic
centers have targeted the dorsolateral prefrontal cortex (DLPFC),
most commonly on the left (e.g., Ref. [10]), but in some cases on the
right [19], or bilaterally [20,21]. The DLPFC is also a common choice
of target in a variety of other neurological and psychiatric condi-
tions, including Alzheimer’s disease [22], ﬁbromyalgia [23], PTSD
[24], OCD [25], anorexia nervosa [7], and alcohol abuse [26].
A signiﬁcant technical challenge in performing rTMS of the
DLPFC lies in accurately locating the appropriate scalp site for coil
placement during treatment. Stimulation of some brain regions,
such as primary motor cortex, elicits direct and measurable re-
sponses such as motor evoked potentials (MEPs), which can then be
used to locate an optimal “motor hotspot” for coil placement.
However, stimulation of DLPFC does not elicit MEPs directly; as a
result, analogousmethods cannot readily be applied for locating the
optimal scalp site for DLPFC-rTMS. Instead, alternative heuristics
based on scalp measurements or neuroimaging techniques are
required.
One of the earliest and most widely used heuristics for locating
theDLPFC is the so-called “5 cmrule”, inwhich themotorhotspot for
the contralateral abductor pollicis brevis muscle is ﬁrst identiﬁed
duringmotor threshold testing, and then a target site is deﬁned 5 cm
anteriorly to this site for DLPFC stimulation [8]. While relatively
simple to perform, the 5 cm method suffers somewhat in accuracy,
and when assessed against MRI, often proves to have located a site
that is outside the DLPFC proper. For example, one large trial found
that this approach missed the DLPFC in as many as 1/3 of patients
undergoing treatment [11]. Likewise, another group [27] found that
the 5 cm rule correctly located the DLPFC in only 7 of 22 subjects.
A more recent study [28] found an average discrepancy of 2 cm
between the site identiﬁed with the 5 cm rule and the MRI-guided
site. In response to such ﬁndings, some studies have adopted a
modiﬁed “6 cm rule” or “7 cm rule”, although these heuristics like-
wise appears less reliable than stereotaxic localization [29].
Notwithstanding such adjustments, the application of any rule
requiring “anterior” measurement upon a curved surface has the
potential to introduce signiﬁcant variability across subjects of
different cranial sizes and geometries; this variability in turn has
the potential to impact upon treatment efﬁcacy. For example, one
study found that the 5 cm rule led to considerable scatter of target
site across the left lateral prefrontal cortex in 54 individuals
undergoing rTMS for major depression; moreover, subjects with
more anterior andmore lateral stimulation sitesweremore likely to
respond to treatment [15]. Likewise, in a randomized comparison in
51 patients, Fitzgerald et al. found signiﬁcantly better outcomes
with DLPFC targeted using MRI-based neuronavigation rather than
the 5 cm rule [30].An alternative approach to the 5 cm rule uses targets deﬁned
with respect to the international 10-20 electroencephalograhy
(EEG) electrode placement system in an attempt to achieve more
consistent coil placement across individuals. The F3 and F4 EEG
electrodes, for example, have been used as approximations of the
scalp sites for left and right DLPFC-rTMS in several studies [31,32].
As an aid for localizing these sites, a recently developed algorithm
known as BeamF3 aims to provide accurate localization of the F3
electrode site from just three measurements: head circumference,
nasion-inion distance, and left tragus-right tragus distance [33]. An
online calculator then provides a polar-coordinate approximation
of the F3 site with respect to the scalp vertex.
The BeamF3 method proposes to circumvent the need for costly,
limited-capacity neuroimaging resources, and offers the additional
advantages of speed and simplicity. However, it remains ques-
tionable how accurately the F3 location actually represents the
DLPFC as identiﬁed using MRI-based neuronavigation. One
comparative study using MRI neuronavigation found that the
DLPFC corresponded more closely to F5, or to an intermediate
location between F3 and F5 [34]. Another recent study [35],
comparing BeamF3 to MRI-based navigation in 12 healthy controls,
found inter-individual site variability of approximately 10 mm
(standard deviation) in Euclidean distance across the three axes of
measurement, suggesting signiﬁcant residual variability in the
stereotaxic site of stimulation.
One additional confounding factor in such studies is that the
DLPFC itself is a large region, heterogenous in both its cytoarchi-
tecture and anatomical connectivity to other regions [36e38]. As
such, the optimal site within the DLPFC itself bears some deﬁning
before the accuracy of BeamF3, the 5 cm rule, or any other heuristic
can be meaningfully assessed. In the setting of depression, a recent
study [14] compared the patterns of whole-brain resting-state
functional connectivity (rsFC) on functional MRI (fMRI) associated
with a variety of DLPFC targets used in previous rTMS studies. The
best clinical efﬁcacy was found in DLPFC targets with a stronger
pattern of rsFC negative correlation to the subgenual cingulate
cortex, previously shown to be an effective target for deep brain
stimulation in the same condition [39]. The study then identiﬁed
stereotaxic coordinates for an ‘optimized’ DLPFC-rTMS target (at
Montreal Neurological Institute coordinates X  38 Y þ 44 Z þ 26)
based on negative correlation of its rsFC to a seed region in the
subgenual cingulate target.
In ideal terms, MRI-guided (or ideally, functional MRI-guided),
individualized neuronavigation could eventually prove to be the
gold standard technique for targeting DLPFC-rTMS in major
depression. In practical terms, with the prevalence of treatment-
resistant depression at approximately 2% of the population [40],
universal implementation of structural or functional MRI-based
neuronavigation could place a prohibitive strain on MRI capacities
and costs, even in relatively wealthy industrialized economies. It is
therefore of interest to quantify how much additional accuracy
is gained by using MRI-guided neuronavigation as opposed to
scalp-based heuristics. It is also of interest to determine whether
existing heuristics might be optimized in order to increase their
agreement with MRI-guided approaches.
In the present study, we aimed to address these questions by
comparing the scalp site for DLPFC stimulation obtained using the
BeamF3 heuristic to that obtained using MRI-guided neuro-
navigation to the target MNI coordinate [X  38 Y þ 44 Z þ 26]
recently identiﬁed as optimal based on clinical efﬁcacy and rsFC. For
the sake of verisimilitude, we performed both types of localization
in a sample of 100MRIs obtained from patients with unipolar major
depression who had enrolled in an ongoing randomized clinical
treatment trial of rTMS applied to the left DLPFC site under MRI
guidance. We then measured the geodesic distance between the
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distribution of discrepancy across the entire sample. Finally, in
order to assess whether the BeamF3 approach might be further
optimized, we performed a statistical comparison to identify any
signiﬁcant, systematic differences in the radial or angular mea-
surements from the vertex to the scalp site under the BeamF3
versus the MRI-guided techniques.Methods
Participants
Participants’ MRIs were obtained from a series of the ﬁrst 100
individuals enrolled in an ongoing randomized clinical trial of rTMS
in unipolar major depressive disorder (ClinicalTrials.gov ID:
NCT01887782). This group consisted of 57 female and 43 male
patients, ages 18e62 (mean 42.1 SD 12.3), 88 right handed, 9 left-
handed, and 3 of mixed handedness based on the Edinburgh
Handedness Inventory. At the time they underwent MRI, all par-
ticipants met DSM-IV diagnostic criteria for a major depressive
disorder, with a score 18 on the 17-item Hamilton Rating Scale for
Depression, having failed at least 1 adequate trial of medication in
the current episode, and with no change in medication regimen in
the 4 weeks prior to scanning. In order tomeet eligibility criteria for
the rTMS trial, all patients were also free of any contraindications to
rTMS or MRI, had no history of neurological injury or illness, and no
history of bipolar or psychotic illness. All patients gave written
informed consent for study participation, and the study was
approved by the Research Ethics Boards of the University Health
Network and the Centre for Addiction and Mental Health.MRI acquisition
All participants underwent MRI on a 3T GE Signa HDx scanner
equipped with an 8-channel phased-array coil. The MRI sequence
used for this study was a T1-weighted fast spoiled gradient echo
anatomical series (TE 12 ms, TI 300 ms, ﬂip angle 20) comprising
116 sagittal slices of 1.5 mm thickness with no gap, a 256  256
matrix and a 240 mm ﬁeld of view, yielding a voxel-wise resolution
of 0.9375  0.9375  1.5 mm. These MRIs were performed in the
week prior to randomization into the trial, to be used for neuro-
navigation; at the time of scanning, participants had not yet
undergone any rTMS sessions or other changes in treatment
regimen.Figure 1. Comparison of scalp sites for BeamF3 versus MRI-guided methods. Using the card
for circumferential arc X and radial arc Y, thereby indicating a scalp location for F3, to be u
traced along the head circumference (A) and the image volume then resliced through the v
Arc Y was then traced along the scalp in this plane (B) to locate the BeamF3 point. The dis
MRI-guided coordinate was then measured (C) to quantify the discrepancy. Finally, the
MRI-guided scalp site rather than the BeamF3 site, in order to measure empirical MRI-guidDetermination of BeamF3 scalp site
The BeamF3 algorithm takes as input 3 scalp measurements: NI,
the nasion-inion distance, TrTr, the left tragus-right tragus distance
through the scalp vertex (at 50% of the nasion-inion distance), and
HC, the head circumference measured through the FPz-Oz plane in
the international 10-20 EEG system in this study, as a more sys-
tematic implementation of the “eyebrow level” HC measurement
recommended in the original description of BeamF3 [33]. From
these 3 measurements, the algorithm returns two values: X, a value
for the length of an arc to be marked leftwards along the head
circumference from the midline, and Y, a value for the radial dis-
tance along a line from the vertex to the point deﬁned at X (see
Fig. 1Cfor illustration).
In order to perform these measurements as accurately as
possible, so as to facilitate comparison of distances between the
neuronavigated and BeamF3 scalp sites, the MRIs were loaded into
Osirix 5.9 software (Pixmeo, Geneva, Switzerland). Next, the stan-
dard scalp landmarks (nasion, inion, left and right tragus) were
manually identiﬁed and landmarked on the images. Next, using the
curvilinear distance measurement tool, distances for NI, TrTr, and
HC were determined in each participant (Fig. 2). These values were
then entered into the freely available BeamF3 desktop application
(clinicalresearcher.org/software.htm) to generate values for dis-
tances X and Y. Point X was then marked along the head circum-
ference plane in Osirix, and theMRI volumewas then resliced along
the plane from the vertex to point X. In this plane, distance Y was
then traced along the scalp to locate F3 according to the BeamF3
method (Fig. 1A and B).Determination of MRI-guided scalp site
In order to identify the scalp site for MRI-guided rTMS of the left
DLPFC as faithfully as possible, the Visor 2.0 neuronavigation sys-
tem (ANT Neuro, Enschede, Netherlands) itself was used to identify
the stimulation target and associated scalp site that was actually
used during MRI-guided rTMS in each individual (Fig. 3). After
loading each subject’s raw MRI images into the Visor software,
standard neuroanatomical landmarks were ﬁrst identiﬁed,
including the anterior commissure, posterior commissure, inter-
hemispheric plane, and extrema of the cortex, to allow deﬁnition of
standard stereotaxic space. Next, the left DLPFC target site was
identiﬁed using the MNI coordinate [X  38 Y þ 44 Z þ 26], pre-
viously identiﬁed as optimal based on functional connectivity andinal scalp measurements (obtained as in Fig. 3), the BeamF3 algorithm returned values
sed in stimulating left DLPFC. The BeamF3-generated measurement for Arc X was ﬁrst
ertical plane from the vertex through point X. The BeamF3-generated measurement for
tance between the BeamF3 scalp site and the scalp site at minimum distance from the
image volume was again resliced in the vertical plane from the vertex through the
ed values for parameters X and Y for comparison to the BeamF3-generated values.
Figure 2. Determination of cardinal scalp measurements for BeamF3 localization of site for left DLPFC stimulation. Using the curvilinear measurement tool in Osirix 5.9 software,
measurements were performed in each subject to determine (A) the length of the nasion-inion scalp surface line along the midline, as well as the positions for the vertex (Cz) at the
midpoint of this line, and the points FPz and Oz at 10% of the nasion-inion distance from each end; (B) the head circumference in the horizontal plane passing through FPz and Oz;
and (C) the length of the left tragus-right tragus scalp line along a plane through the vertex. These measurements served as inputs for the BeamF3 method for locating the scalp
point for left DLPFC stimulation.
A. Mir-Moghtadaei et al. / Brain Stimulation 8 (2015) 965e973968clinical efﬁcacy [14]. Finally, the most proximate point on the scalp
surface to this site was localized, by identifying the voxel on the
scalp surface at minimum Euclidean distance from the target MNIFigure 3. Approach for MRI-based localization of scalp site for left DLPFC stimulation. In ea
localized using the Visor 2.0 neuronavigation system (indicated as DLPFC in this ﬁgure). Next
subject (shown here in coronal, axial, sagittal, and surface-rendered views). Finally, this sca
comparison to scalp-based localization methods as illustrated in Fig. 1.coordinate via manual exploration, followed by a survey of all
adjacent voxels to conﬁrm the identiﬁed voxel as most proximal to
the target coordinate (Fig. 3). This voxel was then marked in thech subject, the site of the MNI stereotaxic coordinate [X  38 Y þ 44 Z þ 26] was ﬁrst
, the scalp site at minimum Euclidean distance from this coordinate was located in each
lp site was marked and the image volume and marker exported in DICOM format for
Table 1
Summary of measurements for DLPFC site localization using BeamF3 and MRI-
guided approaches.
Mean SD Minimum Maximum
Cardinal scalp measurements
Nasion-inion (cm) 36.32 1.74 32.48 41.49
Left tragus-right tragus (cm) 36.51 1.53 33.31 40.52
Head circumference FPz-Oz (cm) 57.31 2.34 52.62 62.44
X parameter measurements
BeamF3 X parameter (cm) 6.62 0.27 6.05 7.12
MRI-guided X parameter (cm) 6.64 0.53 5.25 8.34
BeamF3 X parameter
(% head circumference) 11.54% 0.02% 11.47% 11.62%
MRI-guided X parameter
(% head circumference) 11.58% 0.82% 9.41% 13.83%
Y parameter measurements
BeamF3 Y parameter (cm) 9.60 0.39 8.84 10.68
MRI-guided Y parameter (cm) 9.95 0.80 8.13 11.63
BeamF3 Y parameter
(% nasion-inion) 26.44% 0.43% 25.40% 27.70%
(% tragusetragus) 26.31% 0.56% 24.61% 27.64%
(% avg HC and TrTr) 26.37% 0.08% 26.05% 26.49%
MRI-guided Y parameter
(% nasion-inion)
(% tragusetragus)
(% avg HC and TrTr) 27.32% 1.80% 23.19% 32.15%
Discrepancy measurement
BeamF3 to MRI-guided F3 (cm) 0.70 0.45 0.00 2.06
HC, head circumference; TrTr, tragusetragus distance; SD, standard deviation.
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then exported in DICOM format for comparison to the BeamF3 site
in Osirix software, as below.
Comparison of BeamF3 and neuronavigated scalp sites
In order to derive empirical values for X and Y for the neuro-
navigated scalp sites across the 100 subjects, the centre of the
exported marker from the Visor neuronavigation was located in
Osirix, and the MRI volumewas again resliced along the plane from
the vertex to this marker (Fig. 1). The point of intersection between
this plane and the head circumference was then marked as the
neuronavigated, empirical point X, and the length of the arc along
the head circumference from the midline to this neuronavigated
point X was measured using the curvilinear measurement tool to
deﬁne neuronavigated arc length X in each participant. Likewise,
the length of the arc from the vertex to the neuronavigated scalp
target was measured as neuronavigated length Y.
Finally, in order to determine the absolute values of the
discrepancy between the BeamF3 and the neuronavigated scalp site
in each participant, the curvilinear tool was once again used in
Osirix to measure the distance from the BeamF3 site marked in the
previous step, and the center of the exported marker on the scalp
from the Visor neuronavigation system (Fig. 1C). The absolute
magnitude of this distance was recorded as the neuronavigated-
BeamF3 discrepancy.
Results
Scalp-based measurements
The distribution of scalp-based measurements is summarized in
Table 1. Head circumference through FPz-Oz ranged from 52.62 to
62.44 cm (mean 57.31  SD 2.34 cm). Nasion-inion distance ranged
from 32.48 to 41.49 cm (mean 36.32  SD 1.74 cm). Tragusetragus
distance ranged from 33.31 to 40.52 cm (mean 36.51 SD 1.53 cm).
Applying the BeamF3 algorithm, lengths for the circumferential
arc X ranged from 6.05 to 7.12 cm (mean 6.62  SD 0.27 cm).
Expressed as a percentage of the head circumference through
FPz-Oz in each subject, X ranged from 11.47 to 11.62% (mean
11.54%  SD 0.02%), with 95 of 100 subjects having a value for X in
the range 11.49e11.60% of head circumference (Fig. 4A).
Lengths for the radial arc Y from the vertex to F3 using BeamF3
ranged from 8.84 to 10.68 cm (mean 9.60  SD 0.39 cm). Expressed
as a percentage of the nasion-inion distance in each subject, Y
ranged from 25.40 to 27.70% (mean 26.44%  SD 0.43%). Expressed
as a percentage of the tragusetragus distance in each subject, Y
ranged from 24.61 to 27.64% (mean 26.31%  SD 0.56%). Expressed
as a percentage of the average of the nasion-inion and traguse
tragus distances in each subject, Y ranged from 26.05 to 26.49%
(mean 26.37%  SD 0.08%), with 95 of 100 subjects having a value
for Y in the range 26.18e26.48% of this average value (Fig. 4B).
Neuronavigated measurements
The distribution of empirically-derived, neuronavigated mea-
surements is summarized in Table 1. Lengths for the MRI-guided
circumferential arc X (i.e., the arc from the midline to the point of
intersection between the head circumference and the plane through
the vertex andMRI-guided scalp target) ranged from 5.25 to 8.34 cm
(mean 6.64  SD 0.53 cm). MRI-guided and BeamF3-determined
values for X showed a signiﬁcant correlation across individuals
(r98 ¼ 0.440, P < 0.00001), although the variance of the MRI-guided
values for X was signiﬁcantly higher (F1,99 ¼ 3.67, P ¼ 2.98  1010).
Expressed as a percentage of the head circumference through FPz-Ozin each subject, MRI-guided X ranged from 9.41 to 13.83% (mean
11.58% SD 0.82%), with 90 of 100 individuals having a value for X in
the range 10.08e12.68% of their head circumference (Fig. 4C).
Notably, the within-subjects comparison using paired t-tests yielded
no signiﬁcant difference in the value of X as determined via BeamF3
versus MRI-guided methods, whether on absolute measurements
(BeamF3 6.62  SD 0.27 cm versus MRI-guided 6.64  SD 0.53 cm,
paired t99 ¼ 0.354, P ¼ 0.724) or using percentages of head circum-
ference (BeamF311.54% SD 0.02% versus 11.58% SD 0.82%, paired
t99 ¼ 0.384, P ¼ 0.702).
Lengths for the MRI-guided radial arc Y from the vertex ranged
from 8.13 to 11.63 cm (mean 9.95  SD 0.80 cm). MRI-guided and
BeamF3-determined values for Y showed a signiﬁcant correlation
across individuals (r98 ¼ 0.588, P ¼ 1.23  1010), although the
variance of the MRI-guided values for Y was signiﬁcantly higher
(F1,99 ¼ 3.97, P ¼ 1.97  1011). Expressed as a percentage of the
average of nasion-inion and tragusetragus distance in each subject,
MRI-guided Y ranged from 23.19 to 32.15% (mean 27.32%  SD
1.80%), with 90 of 100 individuals having a value for Y in the range
24.48%e29.94% of their averaged nasion-inion and tragusetragus
distance (Fig. 4D). On within-subjects comparison using paired t-
tests, the value for Y was signiﬁcantly longer when determined by
MRI-guided versus BeamF3 methods, both in absolute terms (MRI-
guided 9.95  SD 0.80 cm versus BeamF3 9.60  SD 0.39 cm,
t99 ¼ 5.342, P < 0.000001) and using percentages of the averaged
nasion-inion and tragusetragus distance (MRI-guided 27.32%  SD
1.80% versus BeamF3 26.37% SD 0.08%, t99¼ 5.300, P< 0.000001).
The MRI-guided Y value was, on average, 3.63% larger than the
BeamF3 Y value. Across individual subjects, MRI-guided Y values
ranged between 2.01 cm longer to 1.13 cm shorter than BeamF3 Y
values (mean 0.35 cm longer  SD 0.65 cm), with 90 of 100
individuals falling in the range 0.63 cm to þ1.39 cm from the
BeamF3 Y value.
Directly measured discrepancies between BeamF3 and MRI-guided
sites
In addition to the statistical comparisons above, we also per-
formed a direct measurement in each subject of the distance
Figure 5. Cumulative distribution for the absolute values of the distance between
BeamF3 and MRI-guided scalp sites. Values for the distance between the scalp site
localized using the BeamF3 approach versus the scalp site localized using the
MRI-guided approach to left DLPFC stimulation, depicted here as a cumulative distri-
bution across the entire patient sample.
Figure 4. Cumulative distributions for X and Y parameters using BeamF3 and MRI-guided approaches. Values for the X and Y localization parameters, expressed in terms relative to
cardinal scalp measurements, are depicted here as cumulative distributions across the entire patient sample for the BeamF3 (A, B) versus the MRI-guided (C, D) scalp sites for left
DLPFC stimulation.
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scalp site identiﬁed by MRI-guided methods (at minimum
Euclidean distance from the MNI coordinate [X 38 Yþ 44 Zþ 26],
as described above in the Methods section). The discrepancy
between BeamF3 and MRI-guided sites ranged from nil to 2.06 cm
(mean 0.70 cm  SD 0.45 cm), with 95 of 100 individuals having
a discrepancy of less than 1.36 cm, 90 of 100 individuals with a
discrepancy of less than 1.30 cm, and 75 of 100 individuals having
a discrepancy of less than 1.00 cm (Fig. 5).
Discussion
To our knowledge, this is the ﬁrst direct comparison of BeamF3
versus MRI-guided targeting methods in a sample of this size in
patients actually about to undergo a course of neuronavigated rTMS
for major depression [41]. A number of salient observations emerge
from the results of the present study. First, the values for X and Y
generated by the BeamF3 heuristic were consistently and accu-
rately approximated by simple percentages of cardinal scalp mea-
surements. X was well approximated as 11.54% of the head
circumference through the FPz-Oz plane, and Y was well approxi-
mated as 26.3e4% of the nasion-inion or tragusetragus distance,
and still more consistently approximated as 26.37% of the average
of these two measurements. These ﬁndings suggest that a simple
set of percentage calculations might reasonably be applied to the
three cardinal scalp measurements, if access to the algorithm were
unavailable. They also suggest that, in the event of small re-
ﬁnements to the BeamF3 algorithm, slightly adjusted percentage
calculations might be able to locate the intended site with
reasonable consistency.Second, a direct measurement of the distance between the
BeamF3 site with the scalp site closest to the optimized coordinate
[X  38 Y þ 44 Z þ 26] revealed a surprisingly close concordance in
the majority of subjects. The average discrepancy was only 0.70 cm,
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1.3 cm of the MRI-guided scalp site, using the BeamF3 method.
Third, although there was no signiﬁcant within-subject differ-
ence in the X measurement using either method, the Y measure-
ment did show a consistent and strongly signiﬁcant within-subject
discrepancy between BeamF3 and MRI-guided methods. This
discrepancy could be annulled by increasing the BeamF3 Y value by
0.35 cm (or 3.63% in relative terms). Thus, even in the absence of a
structural MRI, it appears that the concordance of BeamF3 with the
optimal MRI-guided site may be improved by adjusting the Y but
not the X value.
In order to address the question of whether a modiﬁed BeamF3
method might achieve acceptable concordance with MRI-guided
methods, one must consider the degree of precision that can
reasonably be expected from a neuronavigation suite. Calibration
tolerances for most navigation systems are typically 2e3 mm, and
an experienced technician may reasonably be expected to achieve
targeting tolerances on the order of 1e2 mm during treatment,
based on local clinical experience. Additional error may accrue due
to imperfect identiﬁcation of ﬁduciary landmarks or coregistration
to the MRI at each session, or subtle migration of the head-tracking
markers subsequent to coregistration during the session. All of
these sources of error have the potential to degrade the accuracy of
neuronavigated treatment sessions below 5e6 mm, even under
ideal conditions.
Onemust also consider that there is as yet no accepted consensus
on the ideal stereotaxic coordinates for DLPFC stimulation, either
across groups or in individuals. The stimulation coordinate used in
the present study was identiﬁed as optimal based on analyses of
averaged datasets comprising>100 individuals [14,15,42]. However,
there is considerable heterogeneity in the gross morphology and
stereotaxic position of the DLPFC across individuals [43]. Further-
more, this structural-anatomical variability may be compounded by
functional-anatomical variability in theprecise locationof theDLPFC
region showing peak negative correlation with the subgenual
cingulate cortex [44]. All of these sources of variability may them-
selves contribute in excess of 10 mm of heterogeneity, if not more,
regarding the optimal stimulation target.
In this context, individualized site selection, based on both
structural and functional neuroimaging, may be required for truly
optimal targeting of rTMS within the DLPFC, or many other brain
areas [45,46]. However, at this stage, techniques for individualized
tailoring of the stimulation site and the stimulation pattern are still
relatively new, have relatively few trials assessing their efﬁcacy
over non-individualized regimens [47,48], and have not yet entered
routine use in most therapeutic rTMS facilities. The question
therefore remains whether, for a ﬁxed stereotaxic coordinate in the
DLPFC, the additional logistical burdens and expenses of MRI-
guided neuronavigation are required for precise targeting, or
whether comparable accuracy might also be achieved through
faster, simpler, and much less expensive scalp-based heuristics in a
majority of individuals.
The results of the present study do suggest that an optimized
heuristic, using simple percentages of the three cardinal scalp mea-
sures, can achieve localization accuracies of<1.0 cmwith respect to a
ﬁxed stereotaxic coordinate, in themajority of subjects. In light of the
signiﬁcant anatomical variability of the DLPFC itself, and in light of
the 2e3 cm radii of the ﬁelds commonly employed in therapeutic
rTMSat para-threshold intensities, and in light of the residual sources
of imprecision that hamper even MRI-guided methods, an average
discrepancy of 6.5 mm may be acceptably close to the precision of
neuronavigation for many therapeutic applications.
Several limitations of the present study require acknowledg-
ment. First, it is possible that the software-based methods used for
the cardinal scalp measurements obtained substantially moreprecise or consistent measurements than would be reasonably
achieved using in vivo techniques. Thus, it could be argued that the
real-life precision of in vivo scalp measurement may be less than
observed in the present study. Indeed, to our knowledge, the test-
retest reliability of BeamF3 localization has not yet been system-
atically assessed in vivo. A deﬁnitive assessment of the precision
and consistency of in vivo scalp measurements across several ses-
sions by a given technician, or across several technicians, is beyond
the scope of the present study. However, it should be noted that
inter-session and inter-technician variability are not eliminated by
neuronavigation methods either, as discussed above. Thus the
present study should be understood as limited to comparing the
two methods within the more controlled framework of image-
based analysis. The impact of various sources of in vivo variability,
such as hair density, skull asymmetry, or inter-session or inter-
operator variability, may bear investigation in a future study.
Another potential concern is whether the observed degree of
concordance applies equally across various ethnicities. The present
sample derived from a highly ethnically diverse population in the
downtown Toronto area; due to a high proportion of individuals
with multi-ethnic ancestry, it was felt to be neither possible nor
meaningful to categorize the sample arbitrarily into distinct ethnic
groups. While the ethnic diversity of the sample does allow it to
represent a broader range of human ancestries, the results may still
need to be applied with caution in settings where the patient
population is more homogenous.
Finally, the present study does not directly address the question
of whether scalp-based heuristics such as BeamF3 do indeed match
the clinical efﬁcacy of neuronavigation methods in treating clinical
disorders, such as major depression. The randomized controlled
trial from which the present sample derives employed neuro-
navigated methods for all subjects, and thus is not designed to
address this question. To date, a relatively small number of trials
have directly addressed this issue (e.g., Ref. [30]), and to our
knowledge none have directly compared the BeamF3method to the
stereotaxic coordinate used here. The results of the present study
suggest that the spatial separation between these two scalp sites
is relatively small, in the context of other sources of variation in
target location and coil placement. Further improvements in
treatment efﬁcacy may therefore require individualized functional-
anatomical mapping and optimization of the stimulation pattern
itself, rather than further adjustments to the position of some ﬁxed
coordinate on either the MRI or the scalp.
Conclusions
The present study suggests that the BeamF3 heuristic can
achieve a close approximation of the scalp site used for MRI-guided
stimulation of an optimized, functional-connectivity-based ste-
reotaxic coordinate in the left DLPFC. Minor modiﬁcations to the
radial measurement Ymay further improve the concordance. While
truly individually optimized rTMS may eventually be achieved via
functional mapping and tailored stimulation patterns, such tech-
niques are currently still in development, complex to implement,
and prohibitively expensive when considering the tremendously
large number of cases of treatment-resistant major depression
requiring treatment. Thus, for the time being, in the many settings
where neuronavigation is unavailable or prohibitively expensive, a
modiﬁed BeamF3 heuristic may be an acceptable alternative for
large numbers of patients worldwide.
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